Fluoxymesterone stimulation of tumor marker secretion in patients with breast carcinoma

• Published in: Breast cancer research and treatment Vol. 8; no. 3; pp. 205 - 215
• Main Authors: DILLEY, W. G, HAAGENSEN, D. E. JR, LEIGHT, G. S. JR, SHERE AMMIRATA, DAVIS, S. R, SILVA, J. S, ZAMCHECK, N, LOKICH, J. J, WELLS, S. A. JR
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer 01-01-1986
• Subjects: Apolipoproteins; Apolipoproteins D; Biological and medical sciences; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Carcinoembryonic Antigen - analysis; Carrier Proteins; Cell Line; Female; Fluoxymesterone - therapeutic use; Glycoproteins - blood; Gynecology. Andrology. Obstetrics; Humans; Mammary gland diseases; Medical sciences; Membrane Transport Proteins; Middle Aged; Receptors, Estrogen - analysis; Tumors; Human; Carcinoembryonic antigen; Gross cystic disease fluid protein; Chemotherapy; Synthetic product; Treatment; Androgen; Advanced stage; Tumor; Tumoral marker; Mammary gland; Fluoxymesterone
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/BF01807333

The gross cystic disease fluid protein of 15,000 MW (GCDFP-15) has been demonstrated to be a circulating glycoprotein tumor marker for breast carcinoma in approximately 40% of patients with advanced disease. A recent retrospective analysis of plasma GCDFP-15 levels in patients with advanced breast cancer suggested that androgen therapy could cause significant increases in plasma levels in the absence of disease progression. In order to evaluate the frequency, time course, and intensity of the androgen effect on GCDFP-15 production, a prospective study was initiated. Twenty-nine patients with stage IV breast carcinoma were treated with fluoxymesterone (20 or 30 mg/d). Plasma levels of GCDFP-15 and carcinoembryonic antigen (CEA) were measured by radioimmunoassay before and at various times during therapy. By day 6 of therapy, plasma GCDFP-15 had increased significantly (p = 0.03) from a mean basal level of 58 +/- 12 ng/ml to 160 +/- 60 ng/ml. By contrast, the mean CEA levels in the same patients increased only from 36 +/- 14 ng/ml. The distribution of percent increases in plasma GCDFP-15 was not uniform, but patients with high (greater than 82 ng/ml) basal levels had marked (greater than or equal to 75%) increases in 6/6 (100%) cases, whereas patients with low (less than 30 ng/ml) basal levels had similar increases in only 2/15 (13%) cases. Urinary excretion of GCDFP-15 usually paralleled the increases in plasma levels of the glycoprotein during the first six days of therapy. A linear correlation between percent change in plasma and percent change in urinary GCDFP-15 was demonstrated. A permanent cell line of human breast carcinoma, T47-D, was stimulated to secrete GCDFP-15 in vitro by androgen, but not by estrogen. From these data, we conclude that androgens can specifically stimulate secretion of GCDFP-15 by breast carcinoma tissue in most patients with elevated plasma levels of GCDFP-15, and in some patients with normal levels. The stimulation occurs within days and is not associated with clinical signs of tumor growth.